Skip to main content
Erschienen in: Journal of Gastrointestinal Cancer 1/2015

01.03.2015 | Original Research

Outcomes of Adjuvant Chemoradiation and Predictors of Survival After Extended Cholecystectomy in Gall Bladder Carcinoma: a Single Institution Experience from an Endemic Region

verfasst von: S. Agrawal, P. K. Gupta, N. Rastogi, A. Lawrence, N. Kumari, K. J. Maria Das, R. Saxena

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purpose of the study was to analyse outcomes with adjuvant concurrent chemoradiotherapy (cCRT) followed by adjuvant chemotherapy (AC) in radically resected gall bladder carcinoma (GBC) in Indian patients.

Methods and Materials

We retrospectively reviewed the records of GBC patients who received adjuvant cCRT after extended cholecystectomy (EC) between January 2007 and December 2011. Patterns of recurrence, disease-free survival (DFS), overall survival (OS) and adverse prognostic factors were evaluated.

Results

Thirty-two patients were analysed. At a median follow-up of 53 months, 40 % of patients had recurrence either locoregionally (12 %) or had distant metastases (28 %). The 5-year OS and DFS was 25 % and 53 %, respectively. When prognostic factors were evaluated, the median OS was 51 versus 23 months for node-negative (n = 8) versus node-positive disease (n = 24), not reached versus 34 months for stage 2 (n = 4) versus for stage 3 (n = 28), 46 versus 23 months for R0 (n = 11) versus R1 resection (n = 21), 51 versus 12 months (p = 0.15) for well-differentiated (n = 16) versus poorly differentiated tumours (n = 8), and 10 versus 51 months for lymphovascular invasion presence (n = 4) versus absence (n = 28) (p = 0.01).

Conclusion

Outcome in Indian patients with cCRT followed by AC is similar to that reported in the literature. Adjuvant cCRT followed by AC improves outcomes in patients with R1 and node-positive disease. Advanced stage, nodal positivity, poor differentiation, presence of perineural invasion and lymphovascular invasion are adverse prognostic features. Further research is required with treatment intensification in patients with adverse prognostic factors to improve outcome.
Literatur
1.
Zurück zum Zitat Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer. 2006;118:1591–602.CrossRefPubMed Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer. 2006;118:1591–602.CrossRefPubMed
2.
Zurück zum Zitat Jarnagin WR, Ruo L, Little SA, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer. 2003;98:1689–700.CrossRefPubMed Jarnagin WR, Ruo L, Little SA, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer. 2003;98:1689–700.CrossRefPubMed
3.
Zurück zum Zitat Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract, Tadahiro T, Hodaka A, Hideki Y, Yuji N, Takashi M, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002;95:1685–95.CrossRef Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract, Tadahiro T, Hodaka A, Hideki Y, Yuji N, Takashi M, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002;95:1685–95.CrossRef
4.
Zurück zum Zitat Horgan AM, Eitan A, Thomas W, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30(16):1934–40.CrossRefPubMed Horgan AM, Eitan A, Thomas W, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30(16):1934–40.CrossRefPubMed
5.
Zurück zum Zitat Kim WS, Choi DW, You DD, Han S-S, Kim Y-K, Lee K-W, et al. Risk factors influencing recurrence, patterns of recurrence, and the efficacy of adjuvant therapy after radical resection for gallbladder carcinoma. J Gastrointest Surg. 2010;14:679–87.CrossRefPubMed Kim WS, Choi DW, You DD, Han S-S, Kim Y-K, Lee K-W, et al. Risk factors influencing recurrence, patterns of recurrence, and the efficacy of adjuvant therapy after radical resection for gallbladder carcinoma. J Gastrointest Surg. 2010;14:679–87.CrossRefPubMed
6.
Zurück zum Zitat Mahantshetty UM, Palled SR, Engineer R, Homkar G, Shrivastava SK, Shukla PJ. Adjuvant radiation therapy in gallbladder cancers: 10 years experience at Tata Memorial Hospital. J Cancer Res Ther. 2006;2:52–6.CrossRefPubMed Mahantshetty UM, Palled SR, Engineer R, Homkar G, Shrivastava SK, Shukla PJ. Adjuvant radiation therapy in gallbladder cancers: 10 years experience at Tata Memorial Hospital. J Cancer Res Ther. 2006;2:52–6.CrossRefPubMed
7.
Zurück zum Zitat Yoshioka Y, Ogawa K, Oikawa H, Onishi H, Uchida N, Maebayashi T. Factors influencing survival outcome for radiotherapy for biliary tract cancer: a multicenter retrospective study. Radiother Oncol. 2014;110:546–52.CrossRefPubMed Yoshioka Y, Ogawa K, Oikawa H, Onishi H, Uchida N, Maebayashi T. Factors influencing survival outcome for radiotherapy for biliary tract cancer: a multicenter retrospective study. Radiother Oncol. 2014;110:546–52.CrossRefPubMed
9.
10.
Zurück zum Zitat Wagholikar GD, Behari A, Krishnani N. Early gallbladder cancer. J Am Coll Surg. 2002;194:137–41.CrossRefPubMed Wagholikar GD, Behari A, Krishnani N. Early gallbladder cancer. J Am Coll Surg. 2002;194:137–41.CrossRefPubMed
11.
Zurück zum Zitat Ogura Y, Tabata M, Kawarada Y, Mizumoto R. Effect of hepatic invasion on the choice of hepatic resection for advanced carcinoma of the gallbladder: histologic analysis of 32 surgical cases. World J Surg. 1998;22:262–7.CrossRefPubMed Ogura Y, Tabata M, Kawarada Y, Mizumoto R. Effect of hepatic invasion on the choice of hepatic resection for advanced carcinoma of the gallbladder: histologic analysis of 32 surgical cases. World J Surg. 1998;22:262–7.CrossRefPubMed
12.
Zurück zum Zitat Yamaguchi K, Chijiwa K, Shimizi S. Anatomical limit of extended cholecystectomy for gallbladder carcinoma involving the neck of the gallbladder. Int Surg. 1998;83:21–3.PubMed Yamaguchi K, Chijiwa K, Shimizi S. Anatomical limit of extended cholecystectomy for gallbladder carcinoma involving the neck of the gallbladder. Int Surg. 1998;83:21–3.PubMed
13.
Zurück zum Zitat Todoraki T, Kawamoto T, Takahashi H, Takada Y, Koike N, Otsuka M, et al. Treatment of gallbladder carcinoma by radical resection. Br J Surg. 1999;86:622–7.CrossRef Todoraki T, Kawamoto T, Takahashi H, Takada Y, Koike N, Otsuka M, et al. Treatment of gallbladder carcinoma by radical resection. Br J Surg. 1999;86:622–7.CrossRef
14.
Zurück zum Zitat Gold DG, Miller RC, Haddock MG, Gunderson LL, Quevedo F, Donohue JH, et al. Adjuvant therapy for gallbladder carcinoma. The mayo clinic experience. Int J Radiation Oncology Biol Phys. 2009;75(1):150–5.CrossRef Gold DG, Miller RC, Haddock MG, Gunderson LL, Quevedo F, Donohue JH, et al. Adjuvant therapy for gallbladder carcinoma. The mayo clinic experience. Int J Radiation Oncology Biol Phys. 2009;75(1):150–5.CrossRef
15.
Zurück zum Zitat Müller B, Sola JA, Carcamo M, Ciudad AM, Trujillo C, Cerda B. Adjuvant chemoradiation for resected gallbladder cancer: treatment strategies for one of the leading causes of cancer death in Chilean women. Indian J Cancer. 2013;50:184–8.CrossRefPubMed Müller B, Sola JA, Carcamo M, Ciudad AM, Trujillo C, Cerda B. Adjuvant chemoradiation for resected gallbladder cancer: treatment strategies for one of the leading causes of cancer death in Chilean women. Indian J Cancer. 2013;50:184–8.CrossRefPubMed
16.
Zurück zum Zitat González ME, Giannini OH, González P, Saldaña B. Adjuvant radio-chemotherapy after extended or simple cholecystectomy in gallbladder cancer. Clin Transl Oncol. 2011;13:480–4.CrossRefPubMed González ME, Giannini OH, González P, Saldaña B. Adjuvant radio-chemotherapy after extended or simple cholecystectomy in gallbladder cancer. Clin Transl Oncol. 2011;13:480–4.CrossRefPubMed
17.
Zurück zum Zitat Lim KH, Oh DY, Chie EK, Im SA, Kim TY, et al. Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: which is better in patients with radically resected extrahepatic biliary tract cancer? A nonrandomized, single center study. BMC Cancer. 2009;9:345.CrossRefPubMedCentralPubMed Lim KH, Oh DY, Chie EK, Im SA, Kim TY, et al. Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: which is better in patients with radically resected extrahepatic biliary tract cancer? A nonrandomized, single center study. BMC Cancer. 2009;9:345.CrossRefPubMedCentralPubMed
18.
Zurück zum Zitat Todoraki T, Kawamoto T, Otsuka M, Koike N, Yoshida S, Takada Y. Benefits of combining radiotherapy with aggressive resection for stage IV gallbladder cancer. Hepatogastroenterology. 1999;46:1585–91. Todoraki T, Kawamoto T, Otsuka M, Koike N, Yoshida S, Takada Y. Benefits of combining radiotherapy with aggressive resection for stage IV gallbladder cancer. Hepatogastroenterology. 1999;46:1585–91.
19.
Zurück zum Zitat Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? Cancer. 2002;95:1685–95.CrossRefPubMed Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? Cancer. 2002;95:1685–95.CrossRefPubMed
Metadaten
Titel
Outcomes of Adjuvant Chemoradiation and Predictors of Survival After Extended Cholecystectomy in Gall Bladder Carcinoma: a Single Institution Experience from an Endemic Region
verfasst von
S. Agrawal
P. K. Gupta
N. Rastogi
A. Lawrence
N. Kumari
K. J. Maria Das
R. Saxena
Publikationsdatum
01.03.2015
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Cancer / Ausgabe 1/2015
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-014-9676-x

Weitere Artikel der Ausgabe 1/2015

Journal of Gastrointestinal Cancer 1/2015 Zur Ausgabe

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.